{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","spread":"0","upperLimit":"4.9","value":"2.1"},{"groupId":"OG001","lowerLimit":"39","spread":"39","upperLimit":"59","value":"49"},{"groupId":"OG002","lowerLimit":"41.6","spread":"41.6","upperLimit":"61.5","value":"51.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"97"}],"units":"Participants"}],"description":"Spleen volume was determined by magnetic resonance imaging (MRI) (or computed tomography scan in subjects with contraindications for MRI) at baseline and at the end of cycle 6 with a confirmatory scan approximately 4 weeks after the end of Cycle 6. Analysis was performed on ITT population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo up to 6 cycles (1 cycle=28 days - median exposure= 24 weeks). At the end of cycle 6, participants were crossed-over to SAR302503 400 or 500 mg until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo"},{"description":"SAR302503 400 mg until disease progression and/or unacceptable toxicity (median exposure= 62.1 weeks).","id":"OG001","title":"SAR302503 400 mg"},{"description":"SAR302503 500 mg until disease progression and/or unacceptable toxicity (median exposure =59.7 weeks).","id":"OG002","title":"SAR302503 500 mg"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Baseline, Week 24","title":"Percentage of Participants Who Had >=25% Reduction From Baseline in Volume of Spleen Size at End of Cycle 6","type":"SECONDARY","unitOfMeasure":"percentage of participants"}